Omada Health, Inc.
Rank #72HypergrowthOMDA · Nasdaq · Healthcare
Omada Health, Inc. (OMDA) — Rank #72 by gross profitability (GP/assets 0.52) · ROE -5.1% · Piotroski F-Score 6 / 9.
As-of 2026-09-15 · CIK 0001611115 · all metrics point-in-time as of the filing date.
About
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States.
Show moreShow less
The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners.
The company was incorporated in 2011 and is headquartered in South San Francisco, California.
- Industry
- Health Information Services
- Sector
- Healthcare
- State
- DE
- Filer Category
- Non-accelerated filerEmerging growth company
- Fiscal Year End
- December 31
- Website
- omadahealth.com
Price History
Company Snapshot
P/S is the primary valuation lens — earnings are reinvested, not available for P/E.
Market Cap
$1.24B
P/E (annual)
—
P/S (annual)
4.8
P/B
4.9
P/OCF (annual)
67.9
Shareholder Yield
-374.5%
Employees
946
Industry
Health Information Services
Exchange
Nasdaq
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/2 passTerry Smith quality gate
Passes 1/5 Terry Smith thresholds2 of 5 thresholds not computable from filed data.
What Growth Is Priced In
Implied revenue growth (10Y)
18.4%
The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).
Dilution drag: 374.5% — per-share value needs a total required return of 392.9% once share-count change is priced in.
vs. own 6-year median revenue growth: 53.2%
within its own historyCost-of-equity sensitivity (implied growth at different discount rates)
r = 8%
13.5%
r = 10% (base)
18.4%
r = 12%
22.7%
Net debt / market cap: -29.9%
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / S
Price / revenue per share
P / GP
Price / gross profit per share
Revenue growth and the path to profitability (margin trend) are the primary reads at this stage.
Profitability
Gross profitability (GP / assets)
0.52
Primary signal (Novy-Marx).
4th of 8 SIC 80 peers
Return on equity
-5.1%
Gross margin
65.7%
5th of 8 SIC 80 peers
Revenue growth (YoY)
53.2%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| Revenue vs COGS | |||
| Revenue vs OpEx | |||
| Op. Income vs Revenue |
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.30
1st of 7 SIC 80 peers (best = lowest)
Current ratio
3.91×
2nd of 8 SIC 80 peers
Quick ratio
3.69×
Net cash
$221.71M
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$16.93M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
2.32
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
5.0%
Stock-based comp intensity.
Piotroski F-Score
F-Score
6 / 9
Fundamental-strength score (0-9).